Producto


Plataforma de ensayos de seguridad preclínica
Plataforma de ensayos preclínicos paraevaluación de candidatos a fármacos
 
Safety, adverse drug metabolism (ADME/TOX)and toxicity platform of drug candidates in development:
. Cardiotoxicity: ion channels assays (hERG, Cav1.2, Nav1.5)
. Drug metabolism assays(CYP inhibition and induction, drug stability and metabolite profiling)
. Cytotoxicity
. Genotoxicity (AMES Test)
. Turbidimetry and solubility
Off-target interactions(neurotransmisor receptors, PPARs)
of drug candidates in development:
. Cardiotoxicity: ion channels assays (hERG, Cav1.2, Nav1.5)
. Drug metabolism assays(CYP inhibition and induction, drug stability and metabolite profiling)
. Cytotoxicity
. Genotoxicity (AMES Test)
. Turbidimetry and solubility
Off-target interactions(neurotransmisor receptors, PPARs)

Fundacion MEDINA addresses preclinical issues by identifying potential liabilities of new leads in the early stages of the drug-discovery process:

Drug Metabolism
Cardiotoxicity (Ion channel inhibition)
Cell toxicity
Mitochondrial toxicity
Genotoxicity
Neurotoxicity

Drug Metabolism:
Solubility
Human CYP450 Inhibition & Induction
Microsomal Stability and profiling
Plasma protein binding

Cardiotoxicity (Ion channel inhibition):
hERG
Nav1.5
Cav1.2

Cell toxicity

Mitochondrial toxicity:
Mitochondrial Membrane Potential ROS
Superoxides
Mitochondrial Calcium
ATP/AMP/ADP levels
NADH concentration
Oxygen consumption

Genotoxicity: AMES TEST (Mini-Ames MPF 98/100)

Neurotoxicity: Neurotransmitter Receptors
 
 
 
 
Permalink  
 
Desarrollado por Web4Bio